Drug Profile
Tafetinib
Latest Information Update: 28 Jun 2018
Price :
$50
*
At a glance
- Originator Nanjing Yoko Biomedical
- Class Antineoplastics
- Mechanism of Action Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Jun 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in China (PO)